Terms ending in 2040
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,591,296 | Methods of Preparing Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 11,229,639 | Camptothecin Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 12,747,250 | Camptothecin Derivatives In force · Low confidence | ImmunoGen, Inc. | In force | Low confidence | |
| US 11,834,498 | Biparatopic Fr-Alpha Antibodies and Immunoconjugates In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,701,428 | Therapeutic Combinations Comprising ANTI-CD123 Immunoconjugates In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 12,390,471 | Maytansinoid Derivatives with Self-Immolative Peptide Linkers and Conjugates Thereof In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 11,396,543 | Biparatopic Fr-Alpha Antibodies and Immunoconjugates In force · High confidence | ImmunoGen, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.